Abstract:
Associated pulmonary hypertension worsens the prognosis for patients undergoing scheduled
hemodialysis. Endothelin receptor antagonists, including bosentan, are standard treatment for
pulmonary arterial hypertension. Echocardiography (TTE) remains a key tool for screening and
longitudinal monitoring of the right heart and estimating PH probability. In this cohort, the addition
of bosentan to comprehensive therapy in maintenance hemodialysis patients with pulmonary
hypertension was associated with a marked improvement in pulmonary hemodynamics and right
heart function, demonstrating clinical feasibility in carefully selected hemodialysis patients with
regular safety monitoring.
